IUPAC: 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one · C23H27Cl2N3O2 · MW 448.39 g/mol · CAS 129722-12-9 · ChEMBL1112
Aripiprazole (Abilify · OPC-14597). Third-generation "atypical" antipsychotic and the archetypal dopamine stabilizer — a high-affinity D2/D3 partial agonist rather than a pure blocker. Approved for schizophrenia, bipolar mania, adjunctive major depression, Tourette's, and irritability in autism. Long-acting depot forms: Abilify Maintena, Aristada (aripiprazole lauroxil). It behaves differently from every antagonist antipsychotic on this list — and that difference is the whole story.
Every other antipsychotic on this roster — haloperidol, risperidone, olanzapine, quetiapine — blocks the dopamine D2 receptor. Aripiprazole does not. It binds D2 with sub-nanomolar affinity (Ki ≈ 0.34 nM) but activates it only partially — intrinsic activity roughly 25–30% of dopamine's own maximum at the Gi/o–adenylyl-cyclase axis. This is the defining pharmacology of the third-generation antipsychotics: not a switch, a dimmer.
Because a partial agonist's net effect depends on the ambient agonist tone, aripiprazole behaves as a functional antagonist where dopamine is high (mesolimbic hyperdopaminergia → antipsychotic effect) and a functional agonist where dopamine is low (mesocortical, nigrostriatal, tuberoinfundibular pathways → preserved tone). That single property is why it earned the nickname dopamine stabilizer and why its side-effect signature diverges so sharply from the pure blockers.
Sub-nanomolar orthosteric binding at D2 (Ki ~0.34 nM) with ~25–30% intrinsic activity. Clamps dopaminergic signaling toward an intermediate set-point — dampening excess without producing the full blockade that drives EPS and prolactin elevation.
Aripiprazole is also a high-affinity D3 partial agonist (Ki ~3.3 nM), engaging limbic D3 populations implicated in motivation, reward, and negative symptoms.
Antagonist at 5-HT2A (Ki ~10 nM). Blocking cortical 5-HT2A disinhibits nigrostriatal dopamine release, further lowering extrapyramidal liability — the shared "atypical" mechanism, layered on top of the partial-agonist core.
Partial agonist at 5-HT1A (Ki ~5.6 nM). 5-HT1A agonism is anxiolytic/pro-cognitive and further reduces EPS risk — a favourable contributor to the tolerability profile.
Aripiprazole is a biased D2 ligand: its intrinsic activity is not a single number but varies by pathway (Gi vs β-arrestin vs GIRK) and by the receptor's cellular context. The "partial" label is an average over a signalling landscape.
Additional activity at 5-HT2B (potent), 5-HT7, α1-adrenergic, and H1 histamine receptors. H1/α1 affinity is modest — hence relatively low sedation and orthostasis versus olanzapine or quetiapine.
The clinical corollary is counter-intuitive and important: switching a stable patient from a pure D2 antagonist to aripiprazole can transiently worsen psychosis. Chronic antagonist blockade up-regulates and sensitizes D2 receptors; drop in a partial agonist with intrinsic activity and it can drive those supersensitive receptors, producing rebound psychosis, agitation, or dyskinesia during cross-taper. The dimmer only looks gentle if you respect the wiring behind it.
Aripiprazole is defined pharmacokinetically by extremely slow clearance. Oral bioavailability is ~87%; the terminal half-life of the parent is roughly 75 hours, and its principal metabolite — dehydro-aripiprazole, itself an active D2 partial agonist — runs even longer at ~94 hours, contributing ~40% of steady-state exposure. Consequences: steady state is not reached for about two weeks, dose changes take that long to fully declare themselves, and after stopping, the drug washes out over many days — so adverse effects such as akathisia or impulse-control problems can persist well after the last dose.
Metabolism cascade: parallel dehydrogenation, hydroxylation, and N-dealkylation via CYP2D6 and CYP3A4 converge on the active dehydro metabolite before glucuronidation and excretion.
Dehydro-aripiprazole (marked ★) shares the parent's D2 partial-agonist activity and its long half-life, so the pharmacologically "active moiety" is effectively parent + metabolite pooled. CYP2D6 poor metabolizers (~7–10% of Europeans) clear aripiprazole ~60% slower and require dose reduction; the label mandates halving the dose in known PMs, and quartering it if a PM is also on a strong CYP3A4 inhibitor. Strong CYP3A4 inducers (carbamazepine, rifampicin, St John's Wort) can gut plasma levels and precipitate relapse. Conversely, strong 2D6 inhibitors (fluoxetine, paroxetine, quinidine) or 3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) push levels — and akathisia/impulse-control risk — up.
Partial agonism reshapes the entire clinical profile relative to the antagonist antipsychotics. The trade-offs are real and go in both directions: metabolically and endocrinologically cleaner, but with a distinctive activation signature that the pure blockers rarely produce.
Where phasic dopamine is pathologically elevated, aripiprazole's ~30% ceiling acts as a functional brake — reducing the aberrant salience that underlies positive symptoms (delusions, hallucinations). Efficacy in acute schizophrenia and bipolar mania is comparable to other second-generation agents, without the deep striatal blockade that produces movement disorder.
Pure D2 blockade in the pituitary disinhibits prolactin, causing galactorrhoea, amenorrhoea, and sexual dysfunction. Because aripiprazole supplies partial agonist tone here, it is prolactin-sparing and frequently lowers prolactin — so much so it is used off-label to reverse antipsychotic-induced hyperprolactinaemia.
Extrapyramidal symptoms (parkinsonism, dystonia) and tardive dyskinesia are markedly less common than with haloperidol or risperidone. The exception — and aripiprazole's most characteristic adverse effect — is akathisia: an intense inner restlessness and compulsion to move. It is dose-related, often mistaken for anxiety or worsening psychosis, and one of the leading reasons patients stop the drug.
Low H1 and 5-HT2C engagement means weight gain, dyslipidaemia, and sedation are generally milder than with olanzapine or quetiapine — a major reason it is favoured in first-episode and younger patients. "Activation" (insomnia, agitation, anxiety, restlessness) is the flip side of that same low-sedation, dopaminergic-tone profile.
The pharmacology also produces aripiprazole's most notorious and under-recognised harm: impulse-control disorders. Because it is an agonist at reward-linked D3/D2 populations, a subset of patients develop pathological gambling, compulsive shopping, binge eating, and hypersexuality — behaviours that appear within weeks to months, are frequently not volunteered by the patient, and typically remit on dose reduction or discontinuation. The FDA added a warning in 2016; the EMA and Health Canada issued parallel alerts. It is the same dopaminergic mechanism seen with pramipexole and other agonists in Parkinson's disease.
Aripiprazole is a prescription antipsychotic with a black-box warning (increased mortality in elderly dementia patients; suicidality in young adults). It is not a recreational drug and has low single-agent acute lethality — the real-world harms are akathisia, impulse-control disorders, activation, and interactions. Evidence-based, non-moralistic.
A GPCR is not a two-state switch; it is a Boltzmann-weighted ensemble of conformations, and its Shannon entropy over that ensemble is what agonism actually tunes. A full agonist (dopamine) collapses the receptor toward the transducer-coupled active basin — a large drop in conformational entropy that is paid for by the enthalpy of favourable active-state contacts and by ordering the intracellular G-protein interface. A neutral antagonist (haloperidol, spiperone) locks the inactive basin. Aripiprazole sits between them.
Its ~25–30% intrinsic activity is, thermodynamically, a partial collapse: the ligand shifts the active/inactive population ratio only part-way, leaving a broader, more entropic ensemble than a full agonist would. Functional selectivity — different intrinsic activity at Gi vs β-arrestin vs GIRK — is exactly what you expect when a ligand stabilizes an intermediate conformational distribution rather than a single active micro-state: each transducer reads out a different projection of that softened landscape.
This is where an entropy-aware docking score matters. A rigid ΔG-of-binding calculation that ignores the receptor's residual conformational entropy will mis-rank a partial agonist — it will look like a strong binder (it is: Ki ~0.34 nM) but the score says nothing about efficacy. FlexAID∆S treats the receptor's vibrational/conformational entropy explicitly (ΔG = ΔH − TΔS), so a ligand that binds tightly while leaving the receptor ensemble comparatively soft — a small |ΔS_conf| relative to a full agonist — is flagged as the partial actor it is. The aripiprazole-bound active-state complex shown here (5-HT1A–Gi, PDB 7E2Z) is a single frozen frame of that ensemble; the pharmacology lives in the width of the distribution around it.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
D2
Dopamine D2 receptor (DRD2)
|
Ki ≈ 0.34 nM
range 0.34–1.8 nM · IA ~25–30%
|
Partial agonist | |
|
D3
Dopamine D3 receptor (DRD3)
|
Ki ≈ 3.3 nM
|
Partial agonist | |
|
5-HT1A
Serotonin 1A receptor (HTR1A)
|
Ki ≈ 5.6 nM
|
Partial agonist | |
|
5-HT2A
Serotonin 2A receptor (HTR2A)
|
Ki ≈ 10 nM
range 4–22 nM
|
Antagonist |